Abstract
A series of 1,3-dioxoindan-2-carboxylic acid arylamides were synthesized and evaluated forin vitro cytotoxicity against four human cancer cell lines (HOP62, SK-OV-3, MD-MB-468 and T-47D). The most active was compound 3e (1.2 μM against SK-OV-3 cell line) bearing a 4-methyl substituent.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aoyagi, Y., Kobunai, T., Utsugi, T., Oh-hara, T., and Yamada, Y.,In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II.Jpn. J. Cancer Res., 90, 578–587, (1999) and references cited therein.
Atwell, G. J., Rewcastle, G. W., Baguley, B. C., and Denny, W. A., Potential antitumor agents. 50.In vivo solid tumor activity of derivatives ofN-[2-(dimethylamino)ethyl]acridine- 4-carboxamide.J. Med. Chem., 30, 664–669 (1987).
Baguley, B. C., Zhuang, L., and Marshall, E. M., Experimental solid tumor activity ofN-[2-(dimethylamino)-ethyl] acridine-4- carboxamide.Cancer Chemother. Pharmacol., 36, 244–248 (1995).
Bonner, J. A. and Kozelsky, T. F., The significance of the sequence of administration of topotecan and etoposide.Cancer Chemother. Pharmacol., 39, 109–112 (1996).
Cortes, F. and Pinero, J., Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells.Cancer Chemother. Pharmacol., 34, 411–415 (1994).
Dittrich, C., Coudert, B., Paz-Ares, L., Caponigro, F., Salzberg, M., Gamucci, T., Paoletti, X., Hermans, C., and Lacombe, D., Fumoleau P. and on behalf of the European Organization for Research and Treatment of CancerEarly Clinical Studies Group/New Drug Development Programme (EORTC-ECSG/ NDDP), Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.European J. Cancer, 39, 330–334 (2003)
Kaslow, C. E. and Sommer, N. B., Substituted Lepidines.J. Am. Chem. Soc., 68, 644–646 (1946).
Lee, H., Lee, J., Hong, S-. S., Yang, S-. I., Jung, S.-H., Jahng, Y., and Cho, J., Synthesis andin vitro cytotoxicity of 2- alkylaminosubstituted quinoline derivatives.Arch. Pharm. Res., 23, 450–454 (2000).
Lee, H., Lee, J., and Yang, S-. I., Synthesis andin vitro cytotoxicity of 4-alkyl- or 4-arylaminosubstituted cyclopenta [c]quinoline derivatives.Arch. Pharm. Res., 24, 385–389 (2001).
Minderman, H., Wrzosek, C., Cao, S. S., Utsugi, T., Kobunai, T., Yamada, Y., and Rustum, Y. M., Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells.Cancer Chemother. Pharmacol., 45, 78–84 (2000) and references cited therein.
Potts, K. T., Bhattachaarjee, D., and Walsh E. B., Cycloaddition routes to azaanthraquinone derivatives. 1. use of azadieno- philes.J. Org. Chem., 51, 2011–2021 (1986).
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenny, S., and Boyd, M. R., New colorimetric cytotoxicity assay for anticancer-drug screening.J. Natl. Cancer Inst., 82, 1107–1112 (1990).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jung, J.K., Ryu, J., Yang, S.I. et al. Synthesis andin vitro cytotoxicity of 1,3-dioxoindan-2-carboxylic acid arylamides. Arch Pharm Res 27, 997–1000 (2004). https://doi.org/10.1007/BF02975420
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02975420